Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

6 Months Ended

Jun. 30, 2023

Note 10 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30,		December 31,
	2023		2022
Accrued clinical and development expenditure	$	12,039	$	16,749
Accrued employee expenses		10,020		8,232
Other accrued expenditure		3,028		4,079
Other		155		2,155
	$	25,242	$	31,215